{
  "ticker": "ACL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972873",
  "id": "02972873",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250725",
  "time": "1631",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m4v7jygbg294.pdf",
  "summary": "### **Material Information Summary (ASX Announcement - Form 604)**  \n\n- **Substantial Holder Change**: Allan Gray Australia Pty Ltd increased its voting power in **Australian Clinical Labs (ASX:ACL)** from **10.95% to 12.00%**.  \n- **Shares Acquired**: **2,052,427** ordinary shares bought between **7 Jun 2025 and 23 Jul 2025** at an **average price of ~$2.80/share** (total consideration **AUD 5.74M**).  \n- **Current Holding**: **23,564,705** shares held across multiple custodians (Citibank, JP Morgan, BNP Paribas, etc.).  \n- **Nature of Trades**: All transactions were **on-market, via dividend reinvestment, or capital raising participation**.  \n\n*No other material information identified.*",
  "usage": {
    "prompt_tokens": 2826,
    "completion_tokens": 185,
    "total_tokens": 3011,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-25T06:47:11.369348"
}